<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472693</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 02106</org_study_id>
    <nct_id>NCT00472693</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as&#xD;
      second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine progression-free survival among women receiving bevacizumab + ABI-007 given as second-line combination therapy for hormone receptive negative, Her-2 negative metastatic breast cancer.</measure>
    <time_frame>Study Completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the overall response rate to bevacizumab + ABI-007 in this study population.</measure>
    <time_frame>Study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the toxicity of bevacizumab + ABI-007 in this study population.</measure>
    <time_frame>Study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and ABI-007 (Abraxane)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab and ABI-007 (Abraxane)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab, Abraxane</intervention_name>
    <description>Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.</description>
    <arm_group_label>Bevacizumab and ABI-007 (Abraxane)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, aged 18 years or older and able to give informed consent.&#xD;
&#xD;
          -  Histologically- or cytologically-proven adenocarcinoma of the breast at time of first&#xD;
             diagnosis&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Stage IV disease and have at least one lesion measurable by standard RECIST criteria&#xD;
&#xD;
          -  Disease progression after at least one prior chemotherapy regimen for metastatic&#xD;
             disease or within 12 months of adjuvant chemotherapy initiation.&#xD;
&#xD;
          -  All chemotherapy must be stopped &gt; 2 weeks before enrollment.&#xD;
&#xD;
          -  Primary or metastatic tumor must be negative for estrogen and progesterone receptor&#xD;
             expression. Testing must be done in a CLIA-approved laboratory.&#xD;
&#xD;
          -  Primary or metastatic tumor must have 0 or 1+ staining for HER2/neu identified&#xD;
             immunohistochemically (IHC), by an approved method using one of the standard&#xD;
             monoclonal or polyclonal antibodies (HercepTest, cb-11, PAb1, or TAB250), or if FISH&#xD;
             status is known, it must be negative. Testing must be done in a CLIA-approved&#xD;
             laboratory.&#xD;
&#xD;
          -  Left ventricular ejection fraction must be &gt;= institutional lower limit of normal as&#xD;
             determined by MUGA or echocardiogram&#xD;
&#xD;
          -  Patient must be able to comply with treatment and follow-up procedures:&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function; Absolute neutrophil count &gt;= 1500/mm3;&#xD;
             Hemoglobin &gt;= 10 g/dl; Platelet count &gt;= 100,000/mm3; Creatinine &lt;= 2.0; PTT and&#xD;
             either INR or PT &lt; 1.5x normal; Total bilirubin &lt;= 1.5 X upper limit of normal; AST,&#xD;
             ALT, and alkaline phosphatase &lt;= 2 X upper limit of normal (or &lt;= 5X upper limit of&#xD;
             normal if known liver metastases)&#xD;
&#xD;
          -  If female is of childbearing potential, pregnancy test must be negative and patient&#xD;
             must be willing to use effective contraception while on treatment and for at least 3&#xD;
             months after the last dose of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with VEGF targeted therapy&#xD;
&#xD;
          -  Prior taxane therapy for metastatic disease or for adjuvant therapy within the&#xD;
             previous 12 months&#xD;
&#xD;
          -  History of prior cancer, excluding carcinoma in situ of the cervix and non-melanoma&#xD;
             skin cancers&#xD;
&#xD;
          -  Known CNS disease&#xD;
&#xD;
          -  Inadequately controlled hypertension (defined as systolic blood pressure&gt;150 and/or&#xD;
             diastolic blood pressure&gt;100 mmHg on antihypertensive medications)&#xD;
&#xD;
          -  Any prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection)&#xD;
&#xD;
          -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study enrollment or anticipation of need for major surgical procedure during&#xD;
             the course of the study&#xD;
&#xD;
          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to study enrollment&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study enrollment&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer or bone fracture&#xD;
&#xD;
          -  Proteinuria at screening as demonstrated by either: Urine protein:creatinine (UPC)&#xD;
             ratio &gt;1.0 at screening OR Urine dipstick for proteinuria &gt;2+ (patients discovered to&#xD;
             have &gt;2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine&#xD;
             collection and must demonstrate &lt;1g of protein in 24 hours to be eligible)&#xD;
&#xD;
          -  Patients with active infection&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Radiation therapy within 3 weeks of study entry&#xD;
&#xD;
          -  Patients with hypersensitivity to ABI-007, Chinese hamster ovary cell products, or&#xD;
             other recombinant human antibodies&#xD;
&#xD;
          -  Baseline neuropathy &gt; grade 2&#xD;
&#xD;
          -  Participation in an investigational study of an antineoplastic agent within 4 weeks of&#xD;
             first infusion of this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela DeMichele, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <disposition_first_submitted>April 6, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 9, 2020</disposition_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Second-Line Therapy</keyword>
  <keyword>Triple Negative</keyword>
  <keyword>Her-2 negative</keyword>
  <keyword>Hormone receptor negative</keyword>
  <keyword>Abraxane</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

